Meant Health, a digital health platform that connects patients with licensed clinicians for evaluation, prescription and ongoing care coaching, announced on Saturday that it is expanding telehealth access to FDA-approved GLP-1 medications.
The aim is to shorten the distance between someone wondering whether a treatment might be right for them, and an actual conversation with a US-licensed clinician who could review their history and make that call.
As more people look for a straightforward way to access Ozempic, Meant Health says it is expanding its telehealth platform to connect patients with licensed clinicians for evaluation and prescription. It starts with an intake questionnaire that walks through health history, current medications and what the patient is hoping to address. A licensed clinician then reviews that information and decides, case by case, whether a prescription makes sense.
Ozempic is FDA-approved for the treatment of type 2 diabetes; when it's prescribed for weight management, that use is off-label and remains entirely at the clinician's discretion. Patients who do receive a prescription are paired with ongoing care coaching, providing a steady point of contact as their plan unfolds rather than a one-time appointment.
Lilly reports positive 48-week Phase 2b resu;ts for EloraTZP
Revvity launches IVDR-certified solution for early detection of type 1 diabetes
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Foventa makes key CMO and CFO appointments
Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Nippon Kinzoku begins mass production of ultra-thin stainless steel for insulin needles
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV
Aqua Medical treats second type 2 diabetes patient in IDE trial of investigational PIMA procedure